€10m for crop research
Enlarge image


€10m for crop research

31.07.2012 - The transnational plant genome research funding initiative PLANT-KBBE has published its 6th call: €10m will be provided for crop breeding projects.

The acronym PLANT-KBBE stands for: 'Transnational PLant Alliance for Novel Technologies – towards implementing the Knowledge-Based Bio-Economy in Europe' (PLANT-KBBE) and represents an international funding initiative between France, Spain, Germany and Portugal. National funding partners are the Ministry of Research and Innovation (DGRI) in France, represented by the national funding agency ANR (Agence Nationale de la Recherche), the Ministry of Economy and Competitiveness (MINECO) in Spain, the Federal Ministry of Education and Research (BMBF) in Germany and the Portuguese national funding agency FCT (Fundação para a Ciênca e a Tecnologia). 

Purpose of the call, which is the 6th transnational ‘Call for Proposals’ (‘Food & Feed: crop yields and nutrition security in the context of climate change‘) is the accelerated implementation of practical applications based on achieved scientific findings, accompanied with an immediate transfer of research results in new processes, products and services. The programme targets projects  that are based on the following general research themes: Yield stability, plant health, adaptation to pressures from the environment and phenotypic plasticity. 

The higher purpose of the PLANT-KBBE funding initiative is the implementation, as well as continuation, of transnational research projects between research groups and enterprises of the partner countries mentioned above, with the objective of further deepening the already existing cooperation between economy and science in and between these countries. In the framework of PLANT-KBBE, SMEs are  particularly addressed. The funding partners also intend to support such multi-disciplinary R&D-activities in the context of public-private-partnerships, integrating other research fields apart from plant biotechnology. Full proposals are to be submitted by October 15.


09.10.2015 The US pricing controversy is reverberating halfway across the globe. Shield Therapeutics has taken its IPO plans off the table. Market conditions are too volatile, the company says.


07.10.2015 T-cell specialist Adaptimmune Therapeutics plc needs more space for its R&D in immuno-oncology. The expanding UK company is building a major facility that will house 200 staff.

Drug DiscoveryGermany

06.10.2015 Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.

Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


18.09.2015 AstraZeneca has partnered up with the US Department of Health in order to accelerate the development of new antibiotics. The goal: to be prepared for multi-resistant bugs – and for bioterrorism.


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • ZELTIA (E)4.12 EUR22.99%
  • WILEX (D)2.20 EUR10.00%
  • DEINOVE (F)6.85 EUR7.54%


  • IMMUPHARMA (UK)28.50 GBP-12.98%
  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • THROMBOGENICS (B)4.08 EUR43.7%
  • OREXO (S)65.25 SEK40.9%
  • ZEALAND PHARMA (DK)155.00 DKK26.0%


  • THERAMETRICS (CH)0.04 CHF-33.3%
  • IMMUPHARMA (UK)28.50 GBP-30.1%


  • KARO BIO (S)43.10 SEK5221.0%
  • CHRONTECH PHARMA (S)0.34 SEK325.0%
  • GALAPAGOS (B)38.85 EUR237.5%


  • NEOVACS (F)0.72 EUR-76.7%
  • BIOTEST (D)19.00 EUR-74.8%
  • EVOCUTIS (UK)0.16 GBP-70.9%

No liability assumed, Date: 09.10.2015